Bronconex Acticap

Χώρα: Νέα Ζηλανδία

Γλώσσα: Αγγλικά

Πηγή: Medsafe (Medicines Safety Authority)

Δραστική ουσία:

Mometasone furoate 400ug (anhydrous)

Διαθέσιμο από:

Organon (New Zealand) Limited

INN (Διεθνής Όνομα):

Mometasone furoate 400 µg (anhydrous)

Δοσολογία:

400 mcg/dose

Φαρμακοτεχνική μορφή:

Powder for inhalation

Σύνθεση:

Active: Mometasone furoate 400ug (anhydrous) Excipient: Lactose

Μονάδες σε πακέτο:

Inhaler, metered, DPI, (sample), 14 dose units

Kατηγορία:

Prescription

Τρόπος διάθεσης:

Prescription

Κατασκευάζεται από:

MSD International GmbH (Singapore Branch)

Θεραπευτικές ενδείξεις:

Bronconex Acticap is indicated for prophylactic therapy in the management of patients with asthma of all severities, including patients who have been dependent upon either inhaled or systemically administered corticosteroids and non-corticosteroid-dependent patients inadequately controlled on other drug regimens.

Περίληψη προϊόντος:

Package - Contents - Shelf Life: Inhaler, metered, DPI, (sample) - 14 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 30 dose units - 18 months from date of manufacture stored at or below 25°C - Inhaler, metered, DPI - 60 dose units - 18 months from date of manufacture stored at or below 25°C

Ημερομηνία της άδειας:

2000-12-05